Earlier I wrote What is this Treatment and Why Did We Stop Using it. The first answer, from Dewayne, was the correct answer.
Recent studies suggest that epinephrine doses up to 10 times larger than this produce improved coronary and cerebral hemodynamics and defibrillation rates in animals2,3 and humans.4 Small case series in humans have also suggested that these larger doses given very late in cardiac arrest were more effective in producing initial return of spontaneous circulation, but not in aiding survival.5,6 Clinicians are already using these doses, which equal approximately 15 mg in an adult, despite the absence of better proof of their effectiveness.7-9 
Dewayne wrote –
Sounds like High Dose Epi.
A little later, kindofafireguy wrote –
I agree – sounds like high dose epi. We still give epi for cardiac arrest despite the lack of solid evidence that it improves outcomes.
That is my point in posting about these treatments that we stopped using. We use plenty of treatments without any good evidence – no better than the treatments that we admit are failures.
We need to finally admit that a lot of the treatments we are still using are also failures.
This is comparing three different treatments HDE (High-Dose Epinephrine), SDE (Standard-Dose Epinephrine), and NE (NorEpinephrine). The lines for the HDE and NE are so close to each other, that you may not be able to see the gold line.
We stopped using High-Dose Epinephrine because of this study and at least one other study that had similar outcomes. Most of us in EMS probably never even used NorEpinephrine.
The drugs did not improve outcomes.
There was no good reason to give a drug that did not improve outcomes – as long as we were giving some drug – because we have to feel as if we are making a difference.
We probably are making a difference. We are probably making things worse.
Compare that chart of HDE, SDE, and NE with this chart comparing Epinephrine and No Epinephrine.
Are there any important differences?
We eliminated the treatment that improved ROSC, but did not improve survival and did not improve neurological function – as long as we could give some drug – but we won’t get rid of a treatment that is just as useless when it means that the ALS people will not have a drug to give.
The drug does not work.
The drug may make things worse.
The drug does not make things better.
There is no good reason to continue giving epinephrine outside of randomized controlled trials.
All things are poison and nothing is without poison, only the dose permits something not to be poisonous. - Paracelsus.
We do not appear to have lowered the dose enough for epinephrine to be safe. We don’t know what that dose is and we never will know if we continue to give epinephrine without demanding randomized controlled trials.
 A randomized clinical trial of high-dose epinephrine and norepinephrine vs standard-dose epinephrine in prehospital cardiac arrest.
Callaham M, Madsen CD, Barton CW, Saunders CE, Pointer J.
JAMA. 1992 Nov 18;268(19):2667-72.
PMID: 1433686 [PubMed – indexed for MEDLINE]
 A comparison of repeated high doses and repeated standard doses of epinephrine for cardiac arrest outside the hospital. European Epinephrine Study Group.
Gueugniaud PY, Mols P, Goldstein P, Pham E, Dubien PY, Deweerdt C, Vergnion M, Petit P, Carli P.
N Engl J Med. 1998 Nov 26;339(22):1595-601.
PMID: 9828247 [PubMed – indexed for MEDLINE]
 Prehospital epinephrine use and survival among patients with out-of-hospital cardiac arrest.
Hagihara A, Hasegawa M, Abe T, Nagata T, Wakata Y, Miyazaki S.
JAMA. 2012 Mar 21;307(11):1161-8. doi: 10.1001/jama.2012.294.
PMID: 22436956 [PubMed – indexed for MEDLINE]